Drug Profile
Research programme: non-nucleoside hepatitis C virus NS5B polymerase inhibitors - Genelabs/Novartis
Alternative Names: GL 49174; GL 59728; GL 60667Latest Information Update: 13 Jul 2010
Price :
$50
*
At a glance
- Originator Genelabs Technologies
- Developer Genelabs Technologies; Novartis
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 13 Jul 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
- 04 Nov 2008 Pharmacodynamics data from a preclinical trial of GL 60667 in Hepatitis C presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2008)